Otros idiomas RepliCel Life Sciences Inc.

Acciones

REPCF

CA76027P4006

Mercado cerrado - OTC Markets Otros sitios de cotización 16:20:42 15/03/2024			Varia. Cinco días.	Varia. 1 de enero.
0,0428 ^USD	+4,99 %		-.--%	-4,89 %

2023	RepliCel Life Sciences Inc. informa de los resultados del tercer trimestre y de los nueve meses finalizados el 30 de septiembre de 2023	CI
2023	RepliCel Life Sciences Inc. informa de los resultados del segundo trimestre y de los seis meses finalizados el 30 de junio de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Canadian Investment Regulatory Organization Trading Halt - RP	08/05
RepliCel Life Sciences : Announces Secured Loan Agreement	18/04
RepliCel Life Sciences Inc. Announces Secured Loan Agreement	18/04
RepliCel Life Sciences : announces a Letter of Intent for Asset Purchase Agreement - Form 6-K	20/03
RepliCel Life Sciences : Letter of Intention (Asset Purchase)	18/03
Canadian Investment Regulatory Organization Trading Halt - RP	15/03
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	30/11
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11
RepliCel Life Sciences : Arbitration decision	16/11
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	24/10/23
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/10/23
RepliCel Life Sciences : AGM 2023 Zoom Link and Materials	22/09/23
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	30/08/23
RepliCel Life Sciences : Notice of Meeting and Record Date - Form 6-K	17/08/23
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	17/08/23
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes	17/08/23
REPLICEL LIFE SCIENCES : STATEMENT OF EXECUTIVE COMPENSATION - Form 6-K	10/08/23
RepliCel Life Sciences : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	31/05/23
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	30/05/23
RepliCel Life Sciences : Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options - Form 6-K	18/05/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas RepliCel Life Sciences Inc.

Acciones

REPCF

CA76027P4006

Otros idiomas

Filtros